Amalgamated Bank’s Juno Therapeutics, Inc. JUNO Stock Holding History

Amalgamated Bank’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,131	Closed	-$600K	–	1672
2017 Q4	$600K	Buy	13,131 +1,642	+14%	+$81.9K	0.02%	905
2017 Q3	$515K	Buy	11,489 +589	+5%	+$20.1K	0.02%	930
2017 Q2	$326K	Buy	10,900 +1,741	+19%	+$43K	0.01%	1141
2017 Q1	$203K	Sell	9,159 -1,798	-16%	-$38.6K	0.01%	1375
2016 Q4	$207K	Buy	10,957 +1,165	+12%	+$28.5K	0.01%	1369
2016 Q3	$294K	Buy	9,792 +4	+0%	+$124	0.02%	1032
2016 Q2	$309K	Buy	+9,788	New	+$406K	0.02%	987

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Amalgamated Bank's JUNO Position: Q1 2018 in Review

Amalgamated Bank sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 13,131 shares — an estimated $600K sold.

Amalgamated Bank first reported a position in JUNO in Q2 2016 and held it in 7 quarters. The position peaked at $600K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Amalgamated Bank reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Amalgamated Bank sold 13,131 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $600K.
Amalgamated Bank first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
Amalgamated Bank's Juno Therapeutics, Inc. position peaked at $600K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Amalgamated Bank's 13F filing for Q1 2018, filed 22 May 2018.